Abstract
The description of the allosteric modification of receptors to affect changes in their function requires a model that considers the effects of the modulator on both agonist affinity and efficacy. A model is presented which describes changes in affinity in terms of the constant α (ratio of affinity in the presence vs the absence of modulator) and also the constant ξ (ratio of intrinsic efficacy of the agonist in the presence vs absence of modulator). This allows independent effects of both affinity and efficacy and allows the modeling of any change in the dose-response curve to an agonist after treatment with modulator. Examples are given where this type of model can predict effects of modulators that reduce efficacy but actually increase affinity of agonist (i.e. ifenprodil) and also of modulators that block the action of some agonists (the CXCR4 agonist SDF-1α by the antagonist AMD3100) but not others for the same receptor (SDF-1α peptide fragments RSVM and ASLW).
Keywords: allosteric effects, radioligand binding assay, NMDA receptor, HIV entry, CXCR4, Probe
Current Neuropharmacology
Title: Allosteric Theory: Taking Therapeutic Advantage of the Malleable Nature of GPCRs
Volume: 5 Issue: 3
Author(s): Terry Kenakin
Affiliation:
Keywords: allosteric effects, radioligand binding assay, NMDA receptor, HIV entry, CXCR4, Probe
Abstract: The description of the allosteric modification of receptors to affect changes in their function requires a model that considers the effects of the modulator on both agonist affinity and efficacy. A model is presented which describes changes in affinity in terms of the constant α (ratio of affinity in the presence vs the absence of modulator) and also the constant ξ (ratio of intrinsic efficacy of the agonist in the presence vs absence of modulator). This allows independent effects of both affinity and efficacy and allows the modeling of any change in the dose-response curve to an agonist after treatment with modulator. Examples are given where this type of model can predict effects of modulators that reduce efficacy but actually increase affinity of agonist (i.e. ifenprodil) and also of modulators that block the action of some agonists (the CXCR4 agonist SDF-1α by the antagonist AMD3100) but not others for the same receptor (SDF-1α peptide fragments RSVM and ASLW).
Export Options
About this article
Cite this article as:
Kenakin Terry, Allosteric Theory: Taking Therapeutic Advantage of the Malleable Nature of GPCRs, Current Neuropharmacology 2007; 5 (3) . https://dx.doi.org/10.2174/157015907781695973
DOI https://dx.doi.org/10.2174/157015907781695973 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Why is the Inhibition of the Renin-Angiotensin System Effective for Preventing Cardiac Events in Patients with Coronary Risk Factors or Coronary Artery Disease?
Current Cardiology Reviews Neuropeptide Systems and Schizophrenia
CNS & Neurological Disorders - Drug Targets Progress in the Discovery of Macrocyclic Histone Deacetylase Inhibitors for the Treatment of Cancer
Current Medicinal Chemistry Patent Selections
Recent Patents on Food, Nutrition & Agriculture Preface
Current Neuropharmacology Enhancing Yeast Transcription Analysis Through Integration of Heterogeneous Data
Current Genomics MOP Reduction During Long-Term Methamphetamine Withdrawal was Restored by Chronic Post-Treatment with Fluoxetine
Current Neuropharmacology Editorial: Circadian Rhythms are Everywhere: Except in Neurodegenerative Disorders
Current Alzheimer Research Quantifying Reinforcement Value and Demand for Psychoactive Substances in Humans
Current Drug Abuse Reviews Myelination in Bipolar Patients and the Effects of Mood Stabilizers on Brain Anatomy
Current Pharmaceutical Design Nano-Lipid-Carriers for the Treatment of Vitiligo: A Recent Update, Pathophysiology and Mechanism of Drug Delivery
Current Molecular Pharmacology Personalizing Psychological Treatment Along the IBD Journey: From Diagnosis to Surgery
Current Drug Targets Endothelial Expression of MHC Class II Molecules in Autoimmune Disease
Current Pharmaceutical Design Epigenetics in Multiple Sclerosis: Molecular Mechanisms and Dietary Intervention
Central Nervous System Agents in Medicinal Chemistry Nasal Polyposis: From Pathogenesis to Treatment, An Update
Inflammation & Allergy - Drug Targets (Discontinued) An Effective Brain Imaging Biomarker for AD and aMCI: ALFF in Slow-5 Frequency Band
Current Alzheimer Research Role of GSK-3 in Cardiac Health: Focusing on Cardiac Remodeling and Heart Failure
Current Drug Targets Evolution of Antipsychotic Intervention in the Schizophrenic Psychosis
Current Drug Targets Decreased Regenerative Capacity of Oligodendrocyte Progenitor Cells (NG2-Glia) in the Ageing Brain: A Vicious Cycle of Synaptic Dysfunction, Myelin Loss and Neuronal Disruption?
Current Alzheimer Research Dietary Flavonoids Interaction with CREB-BDNF Pathway: An Unconventional Approach for Comprehensive Management of Epilepsy
Current Neuropharmacology